AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00273793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: incentives are available for reduced smoking on each study visit which occur each weekday.
Study NCT00273793 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contingency Management
Description: incentives are available for reduced smoking on each study visit which occur each weekday.
Study NCT00140582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
Study NCT04424264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid
Description: TDF/FTC/EFV 300/200/600 mg once daily plus RIF/INH 600\*/300 mg daily from screening until enrolment (days -15 to 0)
Study NCT04424264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid
Description: TAF 25 mg + 3TC 300 mg + EFV 600 mg once daily plus RIF/INH 600/\*300 mg daily (days 1 to ≤ 56)
Study NCT04424264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz
Description: TDF/FTC/EFV 300/200/600 mg once daily. RIF/INH 600mg \<70kg, 750mg >70kg
Study NCT01380821 — intervention group
Intervention type: RADIATION
Intervention: Myocardial SPECT
Description: Myocardial SPECT according to clinical standards for patients with a clinical indication to undergo this imaging test.
Study NCT04129008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indobufen and aspirin mimetic
Description: Day 1 to 84±7: The first time: indobufen 100mg + aspirin mimetic; The second time: indobufen 100mg
Study NCT04129008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and indobufen mimetic
Description: Day 1 to 84±7: The first time : aspirin 100mg+ indobufen mimetic; The second time: indobufen mimetic
Study NCT00487461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Description: Comparing two doses of Simvastatin to placebo
Study NCT00487461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT00487461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Description: Comparing two doses of Simvastatin to placebo
Study NCT00619814 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Double-contrast Barium enema, colonoscopy
Description: This is a blinded cohort study comparing double contrast barium enema (DCBE) and colonoscopy in detecting polyps and/or cancer in patients with positive FOBT. Initial evaluation consisted of complete clinical history and physical examination. A DCBE and a colonoscopy were performed in all patients. All polyps identified during colonoscopy were removed and classified by histology. Sensitivity and specificity of DCBE for polyp and/or cancer detection was determined. Tolerability and grade of satisfaction with study procedures was assessed.
Study NCT01544335 — intervention group
Intervention type: OTHER
Intervention: Bioimpedance Spectroscopy
Description: BIS used to measure fluid in arm
Study NCT00350415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks
Study NCT00350415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks
Study NCT03139591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine inhalation; intravenous dexamethasone
Description: 1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.
Study NCT01752777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infectiousness Risk Reduction
Description: Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
Study NCT01752777 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: General Health Improvement
Description: Educational counseling to help link participants to social serves and health related strategies.
Study NCT03198507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHB-105
Description: The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind.
Study NCT03198507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: The intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind.
Study NCT03565094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF28996 solution
Description: Oral solution (0.1-0.2 mg/mL)~Following each cohort, a dosing conference will be held where tolerability, safety and preliminary PK results from the previous cohorts will be reviewed before deciding on the next doses
Study NCT03565094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF28996 capsule
Description: hard capsule orally QD: one dose lower than the highest dose level in part A
Study NCT00241839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.
Study NCT00241839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.
Study NCT00241839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
Study NCT00241839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
Study NCT00241839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium chloride
Description: Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.
Study NCT00241839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium chloride
Description: Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.
Study NCT02675634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test A
Description: Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
Study NCT02675634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test B
Description: Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
Study NCT02675634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subjects own product
Description: The comparator product is the ostomy appliance product that the subject normally uses. This could include products like SenSura , SenSura Mio, Confidence Natural, Moderma Flex and many more. data from the subject own product will be pooled so they appear as one comparator group.
Study NCT00872443 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Collection of characteristics of interauricular septum, characteristics of the CVA, and headache history.~Collection of anamnesis data, surgical past history, especially at the moment of the implement of prothesis, collection of dtat of transthoracic echography, transcranial echodoppler, holter ECG, cerebral MRI.
Study NCT01907035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A cognitive-behavioral intervention
Description: Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with MF plus routine therapy in the field of APS in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
Study NCT01907035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study NCT03193099 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brain imaging
Description: Volume, DWS and DTI
Study NCT03193099 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurological assessments
Description: UHDRS
Study NCT03193099 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychological assessments
Description: STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)
Study NCT03193099 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioural assessments
Description: Computerized game
Study NCT04041414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proud & Empowered!
Description: Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
Study NCT04041414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proud & Empowered!
Description: Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
Study NCT01411891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine impregnated patch (Biopatch)
Description: Patients assigned to the intervention group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
Study NCT02559024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI6469
Description: MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days
Study NCT01121770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux sodium injection
Description: 1.5mg subcutaneously every day
Study NCT01531569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BeneFlax - 38% secoisolariciresinol diglucoside (SDG)
Description: 0.8g of BeneFlax (contains 300mg SDG) given once by mouth
Study NCT02406508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melphalan/HDS
Study NCT02406508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study NCT01059435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered subcutaneously or intravenously
Study NCT01059435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously or intravenously
Study NCT02865213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OBA
Description: The intrusion of posterior teeth using removable appliance OBA.
Study NCT02865213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miniplates
Description: The intrusion of posterior teeth using temporary anchorage Miniplates.
Study NCT02865213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miniscrews
Description: The intrusion of posterior teeth using temporary anchorage Miniscrews.
Study NCT01765257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZILECT®
Study NCT01765257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01153334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)
Description: 1. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
Study NCT01153334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)
Description: 1. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
Study NCT04686669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 capsule formulation
Description: FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.
Study NCT04686669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 tablet formulation
Description: FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.
Study NCT02153749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Regulation of Craving
Description: Regulation strategy practice: Participants will be trained to use a CBT-based cognitive regulation strategy. They will be asked to think of their individualized negative consequences for and thing of them when they see the instruction LATER during the task. Participants will practice using this strategy for multiple cigarette stimuli. High-Risk Situation Practice: Participants will identify 10 situations in which they usually smoke, or are likely to smoke in the next 48 hours. For each situation, they will be asked to practice using the strategy and to plan to use this strategy to regulate craving in daily life.
Study NCT02153749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Regulation of Craving
Description: Each training session in this condition will be identical to the CBT-based training session described, with the exception of the strategy being trained. Specifically, participants will be trained in using the MBT-based strategy (notice craving and accept the feeling without judgment or reaction). To do so, they will be asked to generate their own non- reactive responses to craving (e.g., I can just sit here and notice this. I can ask myself, 'can I be ok with this feeling?') Participants will then be instructed to think of those accepting and non-reactive responses when they see the instruction ACCEPT during the task. All other components will be identical.
Study NCT03103334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zeneo® - Methotrexate
Description: 0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system
Study NCT03103334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Biodim®
Description: 1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection
Study NCT03429270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDOC 5Fr
Description: A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
Study NCT03308370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: 10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride.
Study NCT00409734 — intervention group
Intervention type: BEHAVIORAL
Intervention: Children with pyloric stenosis
Description: Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
Study NCT00409734 — intervention group
Intervention type: BEHAVIORAL
Intervention: Children without pyloric stenosis
Description: Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
Study NCT02812862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiolto® Respimat® (Tiotropium / Olodaterol)
Description: LABA/ LAMA combination therapy:~A combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent.
Study NCT04084691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercice - moderate intensity
Description: standardized physical activity (moderate intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
Study NCT04084691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercice - high intensity
Description: standardized physical activity (high intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
Study NCT04084691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercice - workout
Description: standardized physical activity (bodybuilding) lasting 30 minutes and having a warm-up portion of 5 minutes
Study NCT04084691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal meal
Description: - Hyperlipidic meal Energy supply: 800 kcal Distribution of macronutrients: proteins: 15% +/- 5; carbohydrates: 40% +/- 5; lipids: 45 +/- 5 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market The same meal will be taken before the 3 sessions concerned.
Study NCT04084691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normalized meal
Description: - Hyperglucidic meal Energy supply: 800 kcal Macronutrient distribution: protein 15% +/- 5; carbohydrates 60% +/- 5; lipids 25 +/- 2 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market.~The same meal will be taken before the 3 sessions concerned.
Study NCT04084691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: non meal in the hour before exercise
Study NCT03646396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-daclatasvir
Description: Sofosbuvir-daclatasvir for 3 months
Study NCT03775135 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Different questionnaires about identity development and psychosocial functioning will be administered
Study NCT02252796 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Boost
Description: An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.
Study NCT02252796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given during chemo-radiation phase and optional consolidative phase.
Study NCT02252796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given during chemo-radiation phase and optional consolidative phase.
Study NCT02252796 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided IMRT
Description: Given during chemo-radiation phase
Study NCT03805282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Continuous infusion, variable dose of lidocaine.
Study NCT03805282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Continuous infusion, variable dose of lidocaine.
Study NCT04306341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real time fMRI neurofeedback
Description: Participants will use real time feedback about their amygdala activity to learn to decrease amygdala activity.
Study NCT02561832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: tablets taken orally twice daily
Study NCT02561832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous injections on day one of each cycle
Study NCT02561832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline
Description: The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
Study NCT02561832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines